The stock of Aclaris Therapeutics Inc (NASDAQ:ACRS) last traded at $1.69, up 31.01% from the previous session.
ACRS stock price is now 41.04% away from the 50-day moving average and 40.47% away from the 200-day moving average. The market capitalization of the company currently stands at $120.56M.
, while ‘Evercore ISI’ rates the stock as ‘Outperform’
In other news, Leonard Braden Michael, 10% Owner bought 206,025 shares of the company’s stock on Aug 05 ’24. The stock was bought for $256,357 at an average price of $1.24. Upon completion of the transaction, the 10% Owner now directly owns 14,250,000 shares in the company, valued at $24.08 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 02 ’24, 10% Owner Leonard Braden Michael bought 167,544 shares of the business’s stock. A total of $216,400 was incurred on buying the stock at an average price of $1.29. This leaves the insider owning 14,043,975 shares of the company worth $23.73 million. A total of 5.40% of the company’s stock is owned by insiders.
During the past 12 months, Aclaris Therapeutics Inc has had a low of $0.59 and a high of $5.70. As of last week, the company has a debt-to-equity ratio of 0.02, a current ratio of 7.50, and a quick ratio of 7.50. The fifty day moving average price for ACRS is $1.1982 and a two-hundred day moving average price translates $1.203105 for the stock.
The latest earnings results from Aclaris Therapeutics Inc (NASDAQ: ACRS) was released for 2024-06-30. The net profit margin was -183.28% and return on equity was -37.43% for ACRS. The company reported revenue of $2.77 million for the quarter, compared to $1.87 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 47.99 percent.
